Recombinant LIV-1 (Ladiratuzumab Biosimilar) 抗体
The Human 单克隆 anti-LIV-1 (Ladiratuzumab Biosimilar) antibody is suitable to detect LIV-1 (Ladiratuzumab Biosimilar) in samples from 人. It has been validated for ELISA, BLI, FACS, Func 和 SPR.
产品编号 ABIN7676050
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant LIV-1 (Ladiratuzumab Biosimilar) 抗体 (ABIN7676050)
抗原
LIV-1 (Ladiratuzumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Human
克隆类型
单克隆
标记
This LIV-1 (Ladiratuzumab Biosimilar) antibody is un-conjugated
应用范围
ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
-
-
Expression System
- CHO Cells
-
原理
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab)
-
序列
- QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
产品特性
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
纯度
- >95 %
-
亚型
- IgG1
-
-
anti-LIV-1 (Ladiratuzumab Biosimilar) antibody
Research Grade 适用: 人 ELISA 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: LIV-1 inhibitors
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- LIV-1 (Ladiratuzumab Biosimilar)
-
物质类
- Biosimilar
-
分子量
- 145.5 kDa
-
UniProt
- Q13433
抗原
-
You are here:
